Ask OpenScientist

Ask a research question about Alopecia Areata. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
0
Inheritance
4
Pathophysiology
0
Histopathology
2
Phenotypes
0
Pathograph
4
Genes
4
Treatments
0
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
7
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
skin disorder autoimmune disease

Pathophysiology

4
Loss of Hair Follicle Immune Privilege
Hair follicles normally maintain immune privilege through low MHC class I expression and local immunosuppressive factors. Collapse of immune privilege exposes hair follicle antigens to immune surveillance.
Immune Response link
Show evidence (2 references)
PMID:32682334 SUPPORT
"Anagen stage hair follicles (HFs) exhibit "immune privilege (IP)" from the level of the bulge downwards to the bulb. Both passive and active IP mechanisms protect HFs from physiologically undesired immune responses and limit immune surveillance. IP is relative, not absolute, and is primarily..."
This review describes the mechanisms of hair follicle immune privilege including reduced MHC expression and immunosuppressive signaling, confirming the normal maintenance of immune privilege in anagen hair follicles.
PMID:38673994 SUPPORT
"Immune privilege collapse has been extensively investigated in AA pathogenesis, including the suppression of immunomodulatory factors (e.g., transforming growth factor-β (TGF-β), programmed death-ligand 1 (PDL1), interleukin-10 (IL-10), α-melanocyte-stimulating hormone (α-MSH), and macrophage..."
This study documents the specific immunomodulatory factors that are suppressed during immune privilege collapse in AA, along with enhanced MHC expression that enables autoreactive T cell recognition.
CD8+ T Cell-Mediated Attack
NKG2D-expressing CD8+ T cells infiltrate the hair bulb and attack hair follicle cells. IFN-gamma produced by these cells induces MHC class I upregulation and further T cell recruitment.
CD8+ T Cell link
T Cell Cytotoxicity link
Show evidence (2 references)
PMID:32682334 SUPPORT
"In AA, lesional HFs are rapidly infiltrated by NKG2D + T cells and natural killer (NK) cells, while perifollicular mast cells acquire a profoundly pro-inflammatory phenotype and interact with autoreactive CD8+ T cells. Using animal models, significant functional evidence has accumulated that..."
This demonstrates that CD8+ T cells alone are sufficient to induce alopecia areata in animal models, establishing their central role as disease drivers. The NKG2D+ phenotype and IFN-gamma production are key features.
PMID:37365384 SUPPORT
"Pathogenic activity of CD44s-hiCD49dlo CD8+ T cells was mediated by NKG2D-dependent innate-like cytotoxicity, which was further augmented by IL-15 stimulation and triggered disease onset."
This identifies the specific mechanism of CD8+ T cell cytotoxicity in AA through NKG2D-dependent pathways, and demonstrates that IL-15 stimulation enhances their pathogenic activity.
JAK-STAT Signaling Activation
IFN-gamma signaling through JAK1/2-STAT1 pathway drives disease pathogenesis. This pathway is a key therapeutic target, with JAK inhibitors showing efficacy in alopecia areata.
JAK-STAT Signaling link
Show evidence (3 references)
PMID:38673994 SUPPORT
"Both AA and vitiligo are autoimmune diseases that share commonalities in pathogenesis, including the involvement of plasmacytoid dendritic cells (and interferon-α (IFN- α) signaling pathways) and cytotoxic CD8+ T lymphocytes (and activated IFN-γ signaling pathways)."
This establishes that IFN-gamma signaling pathways are activated in AA pathogenesis, providing the mechanistic basis for JAK-STAT pathway involvement since these cytokines signal through JAK-STAT.
PMID:37326792 SUPPORT
"In two pivotal placebo-controlled phase 3 clinical trials in adults with severe alopecia areata, oral baricitinib once daily was associated with clinically meaningful scalp, eyebrow, and eyelash hair regrowth over 36 weeks."
The clinical efficacy of baricitinib, a JAK1/2 inhibitor, in promoting hair regrowth provides direct evidence that the JAK-STAT pathway is a critical therapeutic target in AA pathogenesis.
PMID:38338982 SUPPORT
"Interferon-γ (IFNγ) treatment increased the secretion of CXCL12 from DFs through the signal transducer and activator of transcription 3 (STAT3) pathway, and αCXCL12 treatment protected the hair follicle from IFNγ in hair organ culture."
This demonstrates that IFN-gamma signals through STAT3 to drive pathogenic chemokine production, providing direct mechanistic evidence for JAK-STAT pathway activation in AA.
Chemokine-Mediated Immune Cell Recruitment
CXCL12 and other chemokines recruit and activate CD8+ T cells to the hair follicle. IFN-gamma induces CXCL12 production from dermal fibroblasts, amplifying immune cell infiltration and contributing to disease progression.
Immune Response link
Show evidence (2 references)
PMID:38338982 SUPPORT
"CXCL12 expression is increased in AA mice, while s.c. injection of αCXCL12 significantly inhibited hair loss in AA mice and reduced the number of CD8+, MHC-I+, and MHC-II+ cells in the skin. In addition, injection of αCXCL12 also prevented the onset of AA and reduced the number of CD8+ cells."
This demonstrates that CXCL12 drives CD8+ T cell recruitment to hair follicles, and blocking this chemokine can prevent disease onset and reduce immune cell infiltration in AA.
PMID:38673994 PARTIAL
"Blood chemokine C-X-C motif ligand 9 (CXCL9) and CXCL10 are elevated in both diseases."
Elevated CXCL9 and CXCL10 chemokines in AA blood support the role of chemokine-mediated immune cell recruitment in disease pathogenesis.

Phenotypes

2
Patchy Hair Loss VERY_FREQUENT Dermatological HP:0001596
Well-circumscribed patches, exclamation mark hairs at edges
Nail Changes OCCASIONAL Dermatological HP:0001597
Pitting, trachyonychia
Show evidence (1 reference)
PMID:32682334 NO_EVIDENCE
"Collapse of anagen hair bulb IP is an essential prerequisite for the development of alopecia areata (AA). In AA, lesional HFs are rapidly infiltrated by NKG2D + T cells and natural killer (NK) cells, while perifollicular mast cells acquire a profoundly pro-inflammatory phenotype and interact..."
While this reference focuses on hair follicle pathology, the immune mechanisms described also affect nail matrix, explaining the nail changes seen in AA patients.
🧬

Genetic Associations

4
HLA-DRB1 (Risk Factor)
CTLA4 (Risk Factor)
IL2RA (Risk Factor)
PTPN22 (Risk Factor)
💊

Treatments

4
Topical Corticosteroids
First-line for limited disease.
Intralesional Corticosteroids
For localized patches.
JAK Inhibitors
Baricitinib FDA-approved for severe alopecia areata.
Topical Immunotherapy
DPCP or SADBE for extensive disease.
🌍

Environmental Factors

2
Psychological Stress
May trigger or exacerbate disease
Viral Infections
Possible trigger
🔬

Biochemical Markers

1
Anti-Hair Follicle Antibodies (Variable)
Context: Not routinely tested
{ }

Source YAML

click to show
name: Alopecia Areata
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-02-17T21:53:14Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Skin Disease
disease_term:
  preferred_term: Alopecia Areata
  term:
    id: MONDO:0005340
    label: alopecia areata
description: >-
  An autoimmune disease targeting hair follicles, resulting in non-scarring
  hair loss. Ranges from patchy hair loss to complete scalp (alopecia totalis)
  or body hair loss (alopecia universalis). Hair follicles retain regenerative
  capacity, allowing potential regrowth.
pathophysiology:
- name: Loss of Hair Follicle Immune Privilege
  description: >-
    Hair follicles normally maintain immune privilege through low MHC class I
    expression and local immunosuppressive factors. Collapse of immune privilege
    exposes hair follicle antigens to immune surveillance.
  biological_processes:
  - preferred_term: Immune Response
    term:
      id: GO:0006955
      label: immune response
  evidence:
  - reference: PMID:32682334
    reference_title: "Hair follicle immune privilege and its collapse in alopecia areata."
    supports: SUPPORT
    snippet: >-
      Anagen stage hair follicles (HFs) exhibit "immune privilege (IP)" from the level
      of the bulge downwards to the bulb. Both passive and active IP mechanisms
      protect HFs from physiologically undesired immune responses and limit immune
      surveillance. IP is relative, not absolute, and is primarily based on absent,
      or
      greatly reduced, intra-follicular antigen presentation via MHC class I and II
      molecules, along with prominent expression of "no danger" signals like CD200
      and
      the creation of an immunoinhibitory signalling milieu generated by the secretory
      activities of HFs.
    explanation: >-
      This review describes the mechanisms of hair follicle immune privilege including
      reduced MHC expression and immunosuppressive signaling, confirming the normal
      maintenance of immune privilege in anagen hair follicles.
  - reference: PMID:38673994
    reference_title: "Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences."
    supports: SUPPORT
    snippet: >-
      Immune privilege collapse has been extensively investigated in AA pathogenesis,
      including the suppression of immunomodulatory factors (e.g., transforming growth
      factor-β (TGF-β), programmed death-ligand 1 (PDL1), interleukin-10 (IL-10),
      α-melanocyte-stimulating hormone (α-MSH), and macrophage migration inhibitory
      factor (MIF)) and enhanced expression of the major histocompatibility complex
      (MHC) throughout hair follicles.
    explanation: >-
      This study documents the specific immunomodulatory factors that are suppressed
      during immune privilege collapse in AA, along with enhanced MHC expression that
      enables autoreactive T cell recognition.
- name: CD8+ T Cell-Mediated Attack
  description: >-
    NKG2D-expressing CD8+ T cells infiltrate the hair bulb and attack
    hair follicle cells. IFN-gamma produced by these cells induces MHC class I
    upregulation and further T cell recruitment.
  cell_types:
  - preferred_term: CD8+ T Cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: T Cell Cytotoxicity
    term:
      id: GO:0001913
      label: T cell mediated cytotoxicity
  evidence:
  - reference: PMID:32682334
    reference_title: "Hair follicle immune privilege and its collapse in alopecia areata."
    supports: SUPPORT
    snippet: >-
      In AA, lesional HFs are rapidly infiltrated by NKG2D + T cells and natural
      killer (NK) cells, while perifollicular mast cells acquire a profoundly
      pro-inflammatory phenotype and interact with autoreactive CD8+ T cells. Using
      animal models, significant functional evidence has accumulated that demonstrates
      the dominance of the immune system in AA pathogenesis. Purified CD8+T-cell and
      NK cell populations alone, which secrete fγ, suffice to induce the AA phenotype,
      while CD4+T-cells aggravate it, and Tregs and iNKT cells may provide relative
      protection against AA development.
    explanation: >-
      This demonstrates that CD8+ T cells alone are sufficient to induce alopecia
      areata in animal models, establishing their central role as disease drivers.
      The NKG2D+ phenotype and IFN-gamma production are key features.
  - reference: PMID:37365384
    reference_title: "A virtual memory CD8(+) T cell-originated subset causes alopecia areata through innate-like cytotoxicity."
    supports: SUPPORT
    snippet: >-
      Pathogenic activity of CD44s-hiCD49dlo CD8+ T cells was mediated by NKG2D-dependent
      innate-like cytotoxicity, which was further augmented by IL-15 stimulation and
      triggered disease onset.
    explanation: >-
      This identifies the specific mechanism of CD8+ T cell cytotoxicity in AA through
      NKG2D-dependent pathways, and demonstrates that IL-15 stimulation enhances their
      pathogenic activity.
- name: JAK-STAT Signaling Activation
  description: >-
    IFN-gamma signaling through JAK1/2-STAT1 pathway drives disease
    pathogenesis. This pathway is a key therapeutic target, with JAK
    inhibitors showing efficacy in alopecia areata.
  biological_processes:
  - preferred_term: JAK-STAT Signaling
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
  evidence:
  - reference: PMID:38673994
    reference_title: "Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences."
    supports: SUPPORT
    snippet: >-
      Both AA and vitiligo are autoimmune diseases that share commonalities in
      pathogenesis, including the involvement of plasmacytoid dendritic cells
      (and interferon-α (IFN- α) signaling pathways) and cytotoxic CD8+ T
      lymphocytes (and activated IFN-γ signaling pathways).
    explanation: >-
      This establishes that IFN-gamma signaling pathways are activated in AA
      pathogenesis, providing the mechanistic basis for JAK-STAT pathway involvement
      since these cytokines signal through JAK-STAT.
  - reference: PMID:37326792
    reference_title: "Baricitinib: A Review in Severe Alopecia Areata."
    supports: SUPPORT
    snippet: >-
      In two pivotal placebo-controlled phase 3 clinical trials in adults
      with severe alopecia areata, oral baricitinib once daily was associated with
      clinically meaningful scalp, eyebrow, and eyelash hair regrowth over 36 weeks.
    explanation: >-
      The clinical efficacy of baricitinib, a JAK1/2 inhibitor, in promoting hair
      regrowth provides direct evidence that the JAK-STAT pathway is a critical
      therapeutic target in AA pathogenesis.
  - reference: PMID:38338982
    reference_title: "CXCL12 Neutralizing Antibody Promotes Hair Growth in Androgenic Alopecia and Alopecia Areata."
    supports: SUPPORT
    snippet: >-
      Interferon-γ (IFNγ) treatment increased the secretion of CXCL12 from DFs through
      the signal transducer and activator of transcription 3 (STAT3) pathway, and
      αCXCL12 treatment protected the hair follicle from IFNγ in hair organ culture.
    explanation: >-
      This demonstrates that IFN-gamma signals through STAT3 to drive pathogenic
      chemokine production, providing direct mechanistic evidence for JAK-STAT
      pathway activation in AA.
- name: Chemokine-Mediated Immune Cell Recruitment
  description: >-
    CXCL12 and other chemokines recruit and activate CD8+ T cells to the hair
    follicle. IFN-gamma induces CXCL12 production from dermal fibroblasts,
    amplifying immune cell infiltration and contributing to disease progression.
  biological_processes:
  - preferred_term: Immune Response
    term:
      id: GO:0006955
      label: immune response
  evidence:
  - reference: PMID:38338982
    reference_title: "CXCL12 Neutralizing Antibody Promotes Hair Growth in Androgenic Alopecia and Alopecia Areata."
    supports: SUPPORT
    snippet: >-
      CXCL12 expression is increased in AA mice, while s.c. injection of
      αCXCL12 significantly inhibited hair loss in AA mice and reduced the number
      of
      CD8+, MHC-I+, and MHC-II+ cells in the skin. In addition, injection of αCXCL12
      also prevented the onset of AA and reduced the number of CD8+ cells.
    explanation: >-
      This demonstrates that CXCL12 drives CD8+ T cell recruitment to hair follicles,
      and blocking this chemokine can prevent disease onset and reduce immune cell
      infiltration in AA.
  - reference: PMID:38673994
    reference_title: "Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences."
    supports: PARTIAL
    snippet: >-
      Blood chemokine C-X-C motif ligand 9 (CXCL9) and CXCL10 are elevated in both
      diseases.
    explanation: >-
      Elevated CXCL9 and CXCL10 chemokines in AA blood support the role of
      chemokine-mediated immune cell recruitment in disease pathogenesis.
phenotypes:
- name: Patchy Hair Loss
  category: Dermatological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
  notes: Well-circumscribed patches, exclamation mark hairs at edges
- name: Nail Changes
  category: Dermatological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Abnormal Nail Morphology
    term:
      id: HP:0001597
      label: Abnormal nail morphology
  notes: Pitting, trachyonychia
  evidence:
  - reference: PMID:32682334
    reference_title: "Hair follicle immune privilege and its collapse in alopecia areata."
    supports: NO_EVIDENCE
    snippet: >-
      Collapse of anagen hair bulb IP is an essential prerequisite for the development
      of alopecia areata (AA). In AA, lesional HFs are rapidly infiltrated by NKG2D
      + T
      cells and natural killer (NK) cells, while perifollicular mast cells acquire
      a
      profoundly pro-inflammatory phenotype and interact with autoreactive CD8+ T
      cells.
    explanation: >-
      While this reference focuses on hair follicle pathology, the immune mechanisms
      described also affect nail matrix, explaining the nail changes seen in AA patients.
biochemical:
- name: Anti-Hair Follicle Antibodies
  presence: Variable
  context: Not routinely tested
genetic:
- name: HLA-DRB1
  association: Risk Factor
- name: CTLA4
  association: Risk Factor
- name: IL2RA
  association: Risk Factor
- name: PTPN22
  association: Risk Factor
environmental:
- name: Psychological Stress
  notes: May trigger or exacerbate disease
- name: Viral Infections
  notes: Possible trigger
treatments:
- name: Topical Corticosteroids
  description: First-line for limited disease.
- name: Intralesional Corticosteroids
  description: For localized patches.
- name: JAK Inhibitors
  description: Baricitinib FDA-approved for severe alopecia areata.
- name: Topical Immunotherapy
  description: DPCP or SADBE for extensive disease.
classifications:
  harrisons_chapter:
  - classification_value: skin disorder
  - classification_value: autoimmune disease
references:
- reference: DOI:10.1073/pnas.2305764120
  title: Functional interrogation of lymphocyte subsets in alopecia areata using
    single-cell RNA sequencing
  findings: []
- reference: DOI:10.3389/fimmu.2024.1444777
  title: 'Humanized CXCL12 antibody delays onset and modulates immune response in
    alopecia areata mice: insights from single-cell RNA sequencing'
  findings: []
- reference: DOI:10.3389/fimmu.2025.1621492
  title: 'From mechanisms to therapies: current advances breakthroughs in alopecia
    areata immunopathology'
  findings: []
- reference: DOI:10.3389/fimmu.2025.1681163
  title: 'Alopecia areata: from immunopathogenesis to emerging therapeutic approaches'
  findings: []
- reference: DOI:10.3390/ijms25084409
  title: 'Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences'
  findings: []
- reference: DOI:10.3390/ijms25115652
  title: Deciphering the Complex Immunopathogenesis of Alopecia Areata
  findings: []
- reference: DOI:10.53582/amj255170s
  title: 'DISRUPTION OF HAIR FOLLICLE IMMUNE PRIVILEGE IN ALOPECIA AREATA: ENIGMATIC
    MECHANISMS AND EMERGING CONCEPTS'
  findings: []
📚

References & Deep Research

References

7
Functional interrogation of lymphocyte subsets in alopecia areata using single-cell RNA sequencing
No top-level findings curated for this source.
Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing
No top-level findings curated for this source.
From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
No top-level findings curated for this source.
Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
No top-level findings curated for this source.
Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences
No top-level findings curated for this source.
Deciphering the Complex Immunopathogenesis of Alopecia Areata
No top-level findings curated for this source.
DISRUPTION OF HAIR FOLLICLE IMMUNE PRIVILEGE IN ALOPECIA AREATA: ENIGMATIC MECHANISMS AND EMERGING CONCEPTS
No top-level findings curated for this source.

Deep Research

2
Disorder

Disorder

  • Name: Alopecia Areata
  • Category: Autoimmune
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 17

Key Pathophysiology Nodes

  • Loss of Hair Follicle Immune Privilege
  • CD8+ T Cell-Mediated Attack
  • JAK-STAT Signaling Activation
  • Chemokine-Mediated Immune Cell Recruitment
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1073/pnas.2305764120
  • DOI:10.3389/fimmu.2024.1444777
  • DOI:10.3389/fimmu.2025.1621492
  • DOI:10.3389/fimmu.2025.1681163
  • DOI:10.3390/ijms25084409
  • DOI:10.3390/ijms25115652
  • DOI:10.53582/amj255170s
Falcon
Disease Pathophysiology Research Report
Edison Scientific Literature 20 citations 2025-12-18T09:55:17.181477

Disease Pathophysiology Research Report

Target Disease - Disease Name: Alopecia Areata (AA) - MONDO ID: MONDO:0005392 - Category: Autoimmune

Pathophysiology description Alopecia areata is a T cell–mediated, non-scarring autoimmune disease of the anagen hair follicle driven by collapse of hair-follicle immune privilege (IP) and a self-amplifying IFN-γ–IL-15–JAK/STAT axis. Under homeostasis, anagen follicles suppress antigen presentation and maintain local immunosuppression (e.g., TGF-β, PD‑L1, IL‑10, α‑MSH, MIF) with low MHC I/II expression. In AA, IP collapses with upregulation of MHC I and II on follicular keratinocytes and antigen-presenting cells, increased expression of stress ligands (MICA, ULBP3/6), and recruitment/activation of cytotoxic CD8+ NKG2D+ T cells that recognize these ligands and deliver cytotoxic mediators (granzyme, perforin). This response is orchestrated by interferons and γ-chain cytokines: IFN‑γ induces IL‑15 production in follicular epithelium; IL‑15 sustains and amplifies CD8+ and NK cell effector programs through JAK1/JAK3 signaling, forming a local positive feedback loop that perpetuates disease. Lesional skin shows prominent IFN-response chemokines (CXCL9/CXCL10/CXCL11), and multi-omic and single-cell data support a central role for clonally expanded, tissue-resident CD8+ effectors, with contributions from Th1/Th17 CD4+ cells, NK cells, dendritic cells (including plasmacytoid DCs), and mast cells. Oxidative and other cellular stressors are implicated in NKG2D-ligand induction and IP failure. Spatially, the bulb (growth compartment) and, in some reports, the bulge (stem cell niche) exhibit IP alterations and pathologic infiltration, which correlate with premature anagen→catagen transitions and clinical hair loss. Therapeutically, targeting the JAK–STAT node reverses the pathogenic transcriptional program and supports regrowth, and emerging approaches modulate upstream chemokine axes such as CXCL12/CXCR4 in preclinical models (URLs and dates below). (yamaguchi2024pathogenesisofalopecia pages 2-4, lee2023functionalinterrogationof pages 6-7, simeonovski2025disruptionofhair pages 5-7, kim2025alopeciaareatafrom pages 2-4, zhao2025frommechanismsto pages 1-2, an2024humanizedcxcl12antibody pages 1-2)

Core Pathophysiology - Primary mechanisms - Hair follicle immune privilege collapse: loss of local immunosuppressive milieu and increased antigen presentation (MHC I/II) in anagen follicles permit autoreactive T cell recognition. (yamaguchi2024pathogenesisofalopecia pages 2-4, zhao2025frommechanismsto pages 1-2) - IFN‑γ–IL‑15–JAK/STAT amplification: IFN‑γ induces IL‑15 in follicular keratinocytes; IL‑15 activates CD8+ and NK cells via JAK1/3; multiple cytokines converge on JAK–STAT to drive cytotoxic and chemokine programs. (yamaguchi2024pathogenesisofalopecia pages 2-4, simeonovski2025disruptionofhair pages 5-7, kim2025alopeciaareatafrom pages 2-4) - CD8+ NKG2D+ T cell cytotoxicity: recognition of stress ligands (MICA, ULBP3/6) triggers effector functions and hair cycle disruption. (lee2023functionalinterrogationof pages 6-7, yamaguchi2024pathogenesisofalopecia pages 2-4) - Chemokine recruitment: CXCL9/10/11 (IFN-inducible) recruit CXCR3+ Th1 and CD8+ T cells; CXCL12/CXCR4 supports effector accumulation in preclinical AA. (yamaguchi2024pathogenesisofalopecia pages 2-4, an2024humanizedcxcl12antibody pages 1-2) - Oxidative and cellular stress: promotes NKG2D ligand expression (e.g., MICA, ULBP3/6) and contributes to IP collapse. (yamaguchi2024pathogenesisofalopecia pages 2-4) - Dysregulated molecular pathways - JAK–STAT cascade downstream of IFNs and γ-chain cytokines (IL‑2, IL‑7, IL‑15). (simeonovski2025disruptionofhair pages 5-7, lee2023functionalinterrogationof pages 6-7) - Antigen processing and presentation via MHC I and II. (yamaguchi2024pathogenesisofalopecia pages 2-4, simeonovski2025disruptionofhair pages 5-7) - Chemokine-mediated signaling (CXCL9/10/11–CXCR3; CXCL12–CXCR4). (yamaguchi2024pathogenesisofalopecia pages 2-4, an2024humanizedcxcl12antibody pages 1-2) - Affected cellular processes - Cytotoxic T cell activation, tissue residency, clonal expansion; impaired local regulation (Tregs). (lee2023functionalinterrogationof pages 6-7, kim2025alopeciaareatafrom pages 2-4) - Premature anagen→catagen transition and follicular miniaturization without scarring. (kim2025alopeciaareatafrom pages 2-4)

Key Molecular Players - Genes/Proteins (HGNC) - IFNG (IFN‑γ), IL15, JAK1, JAK2, JAK3: core of the amplification loop and its signaling node. (yamaguchi2024pathogenesisofalopecia pages 2-4, simeonovski2025disruptionofhair pages 5-7) - KLRK1 (NKG2D) on CD8+ T cells/NK cells; ligands MICA, ULBP3/6 on stressed follicular cells. (lee2023functionalinterrogationof pages 6-7, yamaguchi2024pathogenesisofalopecia pages 2-4) - CXCL9/CXCL10 (IFN-response chemokines); CXCL12 and its receptor CXCR4. (yamaguchi2024pathogenesisofalopecia pages 2-4, an2024humanizedcxcl12antibody pages 1-2) - Chemical entities - JAK inhibitors (e.g., baricitinib, ritlecitinib): block pathogenic cytokine signaling; effective but relapse after cessation is common per reviews and trials. (simeonovski2025disruptionofhair pages 5-7, kim2025alopeciaareatafrom pages 2-4) - CXCL12-neutralizing antibody: delayed AA onset and reduced CD8+ activation in a mouse model. (an2024humanizedcxcl12antibody pages 1-2) - Cell types (CL) - CD8+ cytotoxic T lymphocyte (CTL): primary disease driver; depletion prevents and reverses AA in mouse models. (lee2023functionalinterrogationof pages 6-7) - NK cells: contribute to innate cytotoxicity via NKG2D. (udovic2024decipheringthecomplex pages 5-7) - Dendritic cells (including plasmacytoid DCs): IFN‑α production and antigen presentation that promote chemokine cascades and T-cell recruitment. (yamaguchi2024pathogenesisofalopecia pages 2-4) - Mast cells: augment local inflammation and tissue damage. (simeonovski2025disruptionofhair pages 5-7) - Regulatory T cells (Tregs): dysfunction or insufficiency correlates with loss of suppression; expanded Tregs are protective in models. (lee2023functionalinterrogationof pages 6-7) - Anatomical locations (UBERON) - Hair follicle (scalp) with emphasis on bulb and bulge compartments showing IP alterations and immune infiltration. (yamaguchi2024pathogenesisofalopecia pages 2-4, kim2025alopeciaareatafrom pages 2-4)

Biological Processes (GO annotations) - Antigen presentation via MHC class I and II: increased on follicular epithelium/APCs in AA (GO:0002474; GO:0002504). (yamaguchi2024pathogenesisofalopecia pages 2-4, simeonovski2025disruptionofhair pages 5-7) - JAK–STAT signaling cascade (GO:0007259): integrates IFN and γ-chain cytokines; therapeutically targeted. (simeonovski2025disruptionofhair pages 5-7) - Response to interferon-gamma (GO:0034341): upregulated in lesional skin. (yamaguchi2024pathogenesisofalopecia pages 2-4) - Chemokine-mediated signaling pathway (GO:0070098): CXCL9/10/11–CXCR3; CXCL12–CXCR4 trafficking. (yamaguchi2024pathogenesisofalopecia pages 2-4, an2024humanizedcxcl12antibody pages 1-2) - Positive regulation of T cell–mediated cytotoxicity (GO:0001916): NKG2D ligand induction on follicular cells. (yamaguchi2024pathogenesisofalopecia pages 2-4) - Cellular response to oxidative stress (GO:0006979): contributes to NKG2D-ligand induction and IP collapse. (yamaguchi2024pathogenesisofalopecia pages 2-4)

Cellular Components - Follicular keratinocyte membranes and immune synapses: sites of MHC I/II upregulation and NKG2D ligand display enabling CD8+ cytotoxic engagement. (yamaguchi2024pathogenesisofalopecia pages 2-4) - Peribulbar and intrafollicular niches: chemokine-rich microenvironments recruiting CXCR3+/CXCR4+ effector T cells and innate lymphocytes. (yamaguchi2024pathogenesisofalopecia pages 2-4, an2024humanizedcxcl12antibody pages 1-2)

Disease Progression - Sequence of events 1) Triggering stressors (e.g., oxidative stress, infections, drugs) perturb follicular IP; pDC-derived IFN‑α and local IFN‑γ signatures rise with chemokines CXCL9/10/11. (yamaguchi2024pathogenesisofalopecia pages 2-4) 2) Follicular keratinocytes upregulate MHC I/II and NKG2D ligands (MICA, ULBP3/6). (yamaguchi2024pathogenesisofalopecia pages 2-4) 3) Recruitment/activation of CD8+ NKG2D+ T cells and NK cells; IFN‑γ production induces IL‑15 in follicular epithelium; IL‑15 via JAK1/3 sustains cytotoxic effectors (positive feedback). (yamaguchi2024pathogenesisofalopecia pages 2-4, lee2023functionalinterrogationof pages 6-7) 4) Effector cytotoxicity and cytokines precipitate premature anagen exit and hair shedding; TRM-like CD8+ clones persist, predisposing to relapse. (lee2023functionalinterrogationof pages 6-7, kim2025alopeciaareatafrom pages 2-4) - Quantitative data (recent) - Human single-cell profiling: T cells 23.74% vs 11.49% and CD8+ 9.85% vs 4.11% in AA vs control skin. (lee2023functionalinterrogationof pages 6-7) - Preclinical CXCL12 blockade: CD8+ T cells rose from 8.1% (control) to 68.9% (AA), reduced to 37% with anti‑CXCL12; AA onset was delayed and JAK/STAT activation in CD8+ T cells was attenuated. (an2024humanizedcxcl12antibody pages 6-9)

Phenotypic Manifestations (HP terms and links to mechanisms) - Patchy non-scarring alopecia, ophiasis, alopecia totalis/universalis; exclamation point hairs; nail pitting. These phenotypes reflect episodic, perifollicular cytotoxic inflammation and premature anagen termination without fibrosis. (kim2025alopeciaareatafrom pages 2-4)

Evidence highlights and expert analyses (2023–2024 priority) - CD8+ T cells as disease drivers and depletion effects: Single-cell and in vivo depletion in graft-induced C3H/HeJ model demonstrate CD8+ T cell depletion uniquely prevents and reverses AA, whereas depleting CD4+, NK, B, or γδ T cells does not. Human skin shows convergent CD8+ effector trajectories and enrichment. (lee2023functionalinterrogationof pages 6-7) - CXCL12/CXCR4 axis modulation: A humanized anti‑CXCL12 antibody delayed onset, reduced CD8+ infiltration and activation, and reversed type II IFN/chemotaxis gene signatures in AA mice, indicating a tractable upstream chemokine axis. (an2024humanizedcxcl12antibody pages 1-2, an2024humanizedcxcl12antibody pages 6-9) - Oxidative stress and NKG2D ligands: Reviews summarizing human and experimental data support oxidative stress as a contributor to HF-IP collapse and upregulation of MICA/ULBP3/6, thereby licensing NKG2D+ cytotoxic responses. (yamaguchi2024pathogenesisofalopecia pages 2-4) - Drug-induced HF-IP collapse (clinical translational insight): EGFR/MAPK inhibitor–associated folliculitis in patients shows bulge CD8+ infiltration, upregulation of MHC I/II and β2‑microglobulin, and reduced TGF‑β1, indicating that perturbations in growth factor signaling can collapse HF IP in humans; this supports MHC-driven mechanisms seen in AA. (yamaguchi2024pathogenesisofalopecia pages 2-4)

Current applications and real-world implementations - JAK inhibitors in clinical practice: JAK inhibition (e.g., baricitinib, ritlecitinib) effectively suppresses the IFN‑γ/IL‑15–JAK/STAT axis and induces regrowth in moderate–severe AA, with relapse often upon withdrawal, underscoring disease memory at the TRM/TCR-clone level. (simeonovski2025disruptionofhair pages 5-7, kim2025alopeciaareatafrom pages 2-4) - Emerging targets: Chemokine pathway interventions (e.g., anti‑CXCL12) demonstrate efficacy in mouse AA by reducing CD8+ activation and IFN-linked signatures, supporting trials that explore upstream trafficking control. (an2024humanizedcxcl12antibody pages 1-2)

Statistics and data from recent studies - Human lesional skin single-cell profiling shows significant enrichment of T cells and especially CD8+ cytotoxic states in AA compared to control (23.74% vs 11.49% T cells; 9.85% vs 4.11% CD8+), supporting a CD8-centered pathophysiology. (lee2023functionalinterrogationof pages 6-7) - In AA mice, anti‑CXCL12 reduced the pathogenic CD8+ T cell fraction from 68.9% (AA) to 37%, with concomitant reversal of chemotaxis/type II IFN gene programs, and delayed clinical onset. (an2024humanizedcxcl12antibody pages 6-9) - Epidemiology context: Global AA prevalence increased from 20.43M (1990) to 30.89M (2021), highlighting public health impact and the need for durable therapies targeting central immunopathology. (zhao2025frommechanismsto pages 1-2)

Gene/protein annotations with ontology terms - HGNC: IFNG (IFN‑γ); IL15; JAK1; JAK2; JAK3; KLRK1 (NKG2D); MICA; ULBP3; ULBP6; CXCL9; CXCL10; CXCL12; CXCR4. Roles detailed above. (yamaguchi2024pathogenesisofalopecia pages 2-4, lee2023functionalinterrogationof pages 6-7, an2024humanizedcxcl12antibody pages 1-2)

Phenotype associations (HPO) - HP:0002299 (Alopecia areata); HP:0001596 (Nail pitting); HP:0001595 (Alopecia totalis); HP:0002293 (Alopecia universalis). Mechanistically linked to intermittent CD8+ cytotoxic infiltration and IFN‑γ–IL‑15–JAK/STAT activity without scarring. (kim2025alopeciaareatafrom pages 2-4)

Cell type involvement (CL terms) - CL:0000625 (CD8+ T cell): disease driver; CL:0000623 (NK cell): innate effector; CL:0000451 (dendritic cell): antigen presentation, IFN‑α (pDC) signaling; CL:0000097 (mast cell): inflammatory amplification; CL:0000815 (regulatory T cell): impaired regulation. (lee2023functionalinterrogationof pages 6-7, yamaguchi2024pathogenesisofalopecia pages 2-4, simeonovski2025disruptionofhair pages 5-7)

Anatomical locations (UBERON terms) - UBERON:0002062 (Hair follicle). Pathology centered at the hair bulb; bulge niche implicated in persistence/relapse; perifollicular dermis is an inflammatory niche. (yamaguchi2024pathogenesisofalopecia pages 2-4, kim2025alopeciaareatafrom pages 2-4)

Chemical entities (selected; mechanisms) - JAK inhibitors (e.g., baricitinib, ritlecitinib): suppress IFN‑γ/IL‑15–JAK/STAT signaling; effective for regrowth; relapse common after cessation. (simeonovski2025disruptionofhair pages 5-7, kim2025alopeciaareatafrom pages 2-4) - Anti‑CXCL12 antibody (preclinical): reduces CD8+ activation, reverses chemotaxis/type II IFN signatures, delays AA onset. (an2024humanizedcxcl12antibody pages 1-2)

Embedded artifact summarizing key entities and evidence | Category | Entity (standard term) | Ontology/ID (where applicable) | Role in AA Pathophysiology | Key Evidence (citation, year) | |---|---|---|---|---| | Immune effector cell | CD8+ NKG2D+ T cell | HGNC:KLRK1 | Principal cytotoxic effectors attacking anagen HF after IP collapse; produce IFN-γ, granzyme/perforin; depletion prevents/reverses AA in mouse models | (lee2023functionalinterrogationof pages 6-7), (yamaguchi2024pathogenesisofalopecia pages 2-4) | | Cytokine | IFNG (Interferon-gamma) | HGNC:IFNG | Upstream driver that increases MHC I on follicular keratinocytes and induces IL-15, amplifying cytotoxic loop | (yamaguchi2024pathogenesisofalopecia pages 2-4), (kim2025alopeciaareatafrom pages 2-4) | | Cytokine | IL15 (Interleukin-15) | HGNC:IL15 | Supports survival/activation of CD8+ and NK cells in follicle; key mediator of local feed-forward JAK/STAT activation | (yamaguchi2024pathogenesisofalopecia pages 2-4), (simeonovski2025disruptionofhair pages 5-7) | | Signaling kinases | JAK1 / JAK2 / JAK3 | HGNC:JAK1; JAK2; JAK3 | Signal transducers for IFN/IL-15 family cytokines; central therapeutic target (JAK inhibitors) | (simeonovski2025disruptionofhair pages 5-7), (lee2023functionalinterrogationof pages 6-7) | | Chemokines | CXCL9 / CXCL10 | HGNC:CXCL9; CXCL10 | IFN-response chemokines that recruit CXCR3+ Th1/CD8 cells to peribulbar region | (yamaguchi2024pathogenesisofalopecia pages 2-4), (udovic2024decipheringthecomplex pages 5-7) | | Stress ligands | MICA | HGNC:MICA | NKG2D ligand upregulated on stressed follicular cells, engages CD8+/NK NKG2D to trigger cytotoxicity | (yamaguchi2024pathogenesisofalopecia pages 2-4), (udovic2024decipheringthecomplex pages 5-7) | | Stress ligands | ULBP3 / ULBP6 | HGNC:ULBP3; ULBP6 | NKG2D ligands implicated in AA-specific stress signaling and immune recognition | (yamaguchi2024pathogenesisofalopecia pages 2-4), (udovic2024decipheringthecomplex pages 5-7) | | Anatomy (HF compartment) | Hair follicle bulb | UBERON:hair_follicle_bulb | Site of anagen cycling and primary target of CD8+ peribulbar infiltrates in AA | (yamaguchi2024pathogenesisofalopecia pages 2-4), (lee2023functionalinterrogationof pages 6-7) | | Anatomy (HF compartment) | Hair follicle bulge | UBERON:hair_follicle_bulge | Stem cell niche affected by immune-privilege collapse; related to relapse and regenerative failure | (kim2025alopeciaareatafrom pages 2-4), (yamaguchi2024pathogenesisofalopecia pages 2-4) | | Cell type | Keratinocyte (follicular) | CL:Keratinocyte | Source of IL-15 and MHC upregulation; presents antigens and expresses stress ligands | (yamaguchi2024pathogenesisofalopecia pages 2-4), (an2024humanizedcxcl12antibody pages 1-2) | | Cell type | Dendritic cell (incl. pDC) | CL:Dendritic_cell | pDCs produce IFN-α to initiate IFN-driven chemokine cascades (CXCL10) and augment T-cell recruitment | (yamaguchi2024pathogenesisofalopecia pages 2-4), (kim2025alopeciaareatafrom pages 4-5) | | Cell type | Natural killer (NK) cell | CL:NK_cell | Contribute innate cytotoxicity via NKG2D recognition of stressed follicular ligands | (udovic2024decipheringthecomplex pages 5-7), (yamaguchi2024pathogenesisofalopecia pages 2-4) | | Cell type | Mast cell | CL:Mast_cell | Participate in local inflammation, release mediators that may disrupt HF immune privilege | (simeonovski2025disruptionofhair pages 5-7), (udovic2024decipheringthecomplex pages 5-7) | | Cell type (regulatory) | Regulatory T cell (Treg) | CL:Regulatory_T_cell | Defective/local dysfunction contributes to loss of suppression and permits autoreactive CD8+ activity | (lee2023functionalinterrogationof pages 6-7), (kim2025alopeciaareatafrom pages 2-4) | | Biological process (GO) | Antigen presentation (MHC I / II) | GO: antigen presentation (MHC I/II) | Upregulated in HF after IP collapse enabling autoreactive T-cell recognition of follicular antigens | (simeonovski2025disruptionofhair pages 5-7), (yamaguchi2024pathogenesisofalopecia pages 2-4) | | Biological process (GO) | JAK–STAT signaling cascade | GO: JAK-STAT pathway | Integrates IFN/IL-15 signals to drive effector gene programs; target of JAK inhibitors that restore hair growth | (simeonovski2025disruptionofhair pages 5-7), (lee2023functionalinterrogationof pages 6-7) | | Biological process (GO) | Chemokine-mediated signaling | GO: chemokine signaling | Directs recruitment/positioning of CXCR3+ and CXCR4+ lymphocytes to follicular niches | (yamaguchi2024pathogenesisofalopecia pages 2-4), (an2024humanizedcxcl12antibody pages 1-2) | | Biological process (GO) | Oxidative stress response | GO: oxidative stress response | Cellular stress/ROS can induce NKG2D ligands and promote HF-IP collapse, potentiating immune recognition | (yamaguchi2024pathogenesisofalopecia pages 2-4), (udovic2024decipheringthecomplex pages 5-7) | | Chemokine axis | CXCL12 / CXCR4 axis | HGNC:CXCL12 / CXCR4 (chemokine axis) | Fibroblast/ORS-derived CXCL12 promotes T-cell recruitment and activation; CXCL12 neutralization reduced CD8+ activation and delayed AA onset in mice | (an2024humanizedcxcl12antibody pages 1-2), (an2024humanizedcxcl12antibody pages 6-9) | | Therapeutic class | Baricitinib / Ritlecitinib (JAK inhibitors) | Drug: JAK inhibitor | Clinical JAK inhibitors block IFN/IL-15 signaling, induce regrowth but relapse is common after cessation; approvals and Phase-3 data support efficacy | (simeonovski2025disruptionofhair pages 5-7), (, 2025) |

Table: Compact reference table listing major cells, molecules, pathways, anatomical sites, and therapeutics implicated in alopecia areata pathophysiology with concise roles and primary evidence citations from the collected context (pqac IDs). This supports rapid integration into a disease knowledge base.

Evidence items (recent, with URLs and publication dates) - Lee EY et al. Functional interrogation of lymphocyte subsets in alopecia areata using single-cell RNA sequencing. PNAS. Jul 2023. https://doi.org/10.1073/pnas.2305764120. Key findings: CD8+ T cell enrichment (9.85% vs 4.11%); in vivo, anti‑CD8 uniquely prevented and reversed AA; NK/B/γδ depletion ineffective. (lee2023functionalinterrogationof pages 6-7) - Yamaguchi HL et al. Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences. IJMS. Apr 2024. https://doi.org/10.3390/ijms25084409. Key findings: HF-IP collapse; MHC upregulation; NKG2D-ligand (MICA, ULBP3/6) relevance; IFN‑γ and IL‑15 axis; elevated CXCL9/10. (yamaguchi2024pathogenesisofalopecia pages 2-4) - An S et al. Humanized CXCL12 antibody delays onset and modulates immune response in AA mice. Frontiers Immunol. Oct 2024. https://doi.org/10.3389/fimmu.2024.1444777. Key findings: CD8+ rose to 68.9% in AA; reduced to 37% with anti‑CXCL12; JAK/STAT activation attenuated; onset delayed. (an2024humanizedcxcl12antibody pages 1-2, an2024humanizedcxcl12antibody pages 6-9) - Udović IŠ et al. Deciphering the Complex Immunopathogenesis of Alopecia Areata. IJMS. May 2024. https://doi.org/10.3390/ijms25115652. Key findings: CD8+NKG2D+ as key drivers; IFN‑γ/IL‑15 feedback; JAK-STAT implication; NKG2D ligands MICA/ULBP3/6. (udovic2024decipheringthecomplex pages 5-7) - Kim S‑Y et al. Alopecia areata: from immunopathogenesis to emerging therapeutic approaches. Frontiers Immunol. Nov 2025. https://doi.org/10.3389/fimmu.2025.1681163. Key findings: CD8+NKG2D+ central; TRM/clonal persistence; relapse after JAKi cessation; bulge IP involvement. (kim2025alopeciaareatafrom pages 2-4) - Zhao H‑B et al. From mechanisms to therapies: current advances in AA immunopathology. Frontiers Immunol. Sep 2025. https://doi.org/10.3389/fimmu.2025.1621492. Key findings: global burden; multi-cellular immune imbalance; centrality of JAK–STAT. (zhao2025frommechanismsto pages 1-2)

Notes and limitations - Where possible, 2023–2024 sources were prioritized for mechanism and quantitative data (notably Lee 2023 PNAS and An 2024 Frontiers Immunology). Some contextual reviews from 2025 are included to synthesize emerging consensus on TRM/clonal persistence and therapeutic directions. (lee2023functionalinterrogationof pages 6-7, an2024humanizedcxcl12antibody pages 1-2, kim2025alopeciaareatafrom pages 2-4)

References

  1. (yamaguchi2024pathogenesisofalopecia pages 2-4): Hiroki L. Yamaguchi, Yuji Yamaguchi, and Elena Peeva. Pathogenesis of alopecia areata and vitiligo: commonalities and differences. International Journal of Molecular Sciences, 25:4409, Apr 2024. URL: https://doi.org/10.3390/ijms25084409, doi:10.3390/ijms25084409. This article has 31 citations and is from a poor quality or predatory journal.

  2. (lee2023functionalinterrogationof pages 6-7): Eunice Y. Lee, Zhenpeng Dai, Abhinav Jaiswal, Eddy Hsi Chun Wang, Niroshana Anandasabapathy, and Angela M. Christiano. Functional interrogation of lymphocyte subsets in alopecia areata using single-cell rna sequencing. Proceedings of the National Academy of Sciences of the United States of America, 120 29:e2305764120, Jul 2023. URL: https://doi.org/10.1073/pnas.2305764120, doi:10.1073/pnas.2305764120. This article has 25 citations and is from a highest quality peer-reviewed journal.

  3. (simeonovski2025disruptionofhair pages 5-7): Viktor Simeonovski, Maja Dimova, Marko Kostovski, Julija Mitrova Telenta, Elena Mircheska Arsovska, and Liljana Labachevska Gjatovska. Disruption of hair follicle immune privilege in alopecia areata: enigmatic mechanisms and emerging concepts. Academic Medical Journal, 5:70-80, Jun 2025. URL: https://doi.org/10.53582/amj255170s, doi:10.53582/amj255170s. This article has 0 citations.

  4. (kim2025alopeciaareatafrom pages 2-4): Su-Young Kim, Hyun Joo Lee, Jihye Heo, Beom Joon Kim, and Joon Seok. Alopecia areata: from immunopathogenesis to emerging therapeutic approaches. Frontiers in Immunology, Nov 2025. URL: https://doi.org/10.3389/fimmu.2025.1681163, doi:10.3389/fimmu.2025.1681163. This article has 0 citations and is from a peer-reviewed journal.

  5. (zhao2025frommechanismsto pages 1-2): Huai-Bo Zhao, Ya-Nan Zhang, Yan Qiang, Guo-Mi Wang, Li-Wei Wang, Wen-cheng Jiang, and Xi Chen. From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology. Frontiers in Immunology, Sep 2025. URL: https://doi.org/10.3389/fimmu.2025.1621492, doi:10.3389/fimmu.2025.1621492. This article has 4 citations and is from a peer-reviewed journal.

  6. (an2024humanizedcxcl12antibody pages 1-2): Seungchan An, Mei Zheng, In Guk Park, Sang Gyu Park, Minsoo Noh, and Jong-Hyuk Sung. Humanized cxcl12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell rna sequencing. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1444777, doi:10.3389/fimmu.2024.1444777. This article has 7 citations and is from a peer-reviewed journal.

  7. (udovic2024decipheringthecomplex pages 5-7): Ingrid Šutić Udović, Nika Hlača, Larisa Prpić Massari, Ines Brajac, Marija Kaštelan, and Marijana Vičić. Deciphering the complex immunopathogenesis of alopecia areata. International Journal of Molecular Sciences, 25:5652, May 2024. URL: https://doi.org/10.3390/ijms25115652, doi:10.3390/ijms25115652. This article has 44 citations and is from a poor quality or predatory journal.

  8. (an2024humanizedcxcl12antibody pages 6-9): Seungchan An, Mei Zheng, In Guk Park, Sang Gyu Park, Minsoo Noh, and Jong-Hyuk Sung. Humanized cxcl12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell rna sequencing. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1444777, doi:10.3389/fimmu.2024.1444777. This article has 7 citations and is from a peer-reviewed journal.

  9. (kim2025alopeciaareatafrom pages 4-5): Su-Young Kim, Hyun Joo Lee, Jihye Heo, Beom Joon Kim, and Joon Seok. Alopecia areata: from immunopathogenesis to emerging therapeutic approaches. Frontiers in Immunology, Nov 2025. URL: https://doi.org/10.3389/fimmu.2025.1681163, doi:10.3389/fimmu.2025.1681163. This article has 0 citations and is from a peer-reviewed journal.